Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J, Mant T, Rosano M, Huntenburg C, Alai-Safar M, Darne S, Palmer D, Pavlova BG, Doralt J, Reeve R, Goel N, Weilert D, Rhyne PW, Chance K, Caminis J, Roach J, Ganguly T.
Hillson J, et al. Among authors: mant t.
Pharmacol Res Perspect. 2018 Feb;6(1):e00380. doi: 10.1002/prp2.380.
Pharmacol Res Perspect. 2018.
PMID: 29417761
Free PMC article.
Clinical Trial.